Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primary Lymphedema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Primary Lymphedema. Displaying page 1 of 1.
    EudraCT Number: 2013-001360-36 Sponsor Protocol Number: LF-DML-MS Start Date*: 2013-09-30
    Sponsor Name:ULB - Unité de Recherche en Lymphologie - Faculté des Sciences de la motricité
    Full Title: Evaluation of the benefit of lymphofluoroscopy in the validation of the manual drainage techniques on lymphedema
    Medical condition: upper limb lymphedema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004443-20 Sponsor Protocol Number: HP-LY-CL-2063 Start Date*: 2018-05-07
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph nod...
    Medical condition: Secondary lymphedema associated with the treatment of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10036389 Postmastectomy lymphedema syndrome LLT
    20.0 100000004866 10025233 Lymphedema LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004403-12 Sponsor Protocol Number: APHP190871 Start Date*: 2020-10-26
    Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
    Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study
    Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004501-24 Sponsor Protocol Number: CT-2011-01 Start Date*: 2012-03-06
    Sponsor Name:CureTech Ltd.
    Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022239-12 Sponsor Protocol Number: ISIS 183750-CS3 Start Date*: 2011-05-05
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-003714-27 Sponsor Protocol Number: P160601J Start Date*: 2017-10-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: KAPKEY: Phase II multicentric study of pembrolizumab in classic or endemic Kaposi's sarcoma
    Medical condition: classical and endemic Kaposi's patient with progressive disease,
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023284 Kaposi's sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005846-39 Sponsor Protocol Number: GISG-06 Start Date*: 2014-07-22
    Sponsor Name:University of Heidelberg
    Full Title: Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxe...
    Medical condition: Advanced and relapsed angiosarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002481 Angiosarcoma stage unspecified LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072814 Breast angiosarcoma metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072813 Breast angiosarcoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025223 Lymphangiosarcoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025224 Lymphangiosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057700 Angiosarcoma non-metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002480 Angiosarcoma recurrent PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018827 Haemangiosarcoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072891 Skin angiosarcoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067388 Hepatic angiosarcoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002477 Angiosarcoma metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002476 Angiosarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:37:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA